A Phase 4 interventional study of Tirzepatide and Placebo in Obesity (Disorder), sponsored by University Medical Centre Ljubljana. Recruiting at 2 sites in Slovenia. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by University Medical Centre Ljubljana · Phase 4, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies testing tirzepatide in Obesity — 62 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.
Among the 106 studies testing tirzepatide in Obesity, this one is the 85th largest by planned enrollment, is one of 38 that started in 2026, is one of 30 in phase 4, reaches primary completion later than 42 of the 78 other live ones, and was the 106th registered.
11,564 studies on the registry are indexed under Obesity; 2,059 are open to participants now.
Browse Obesity studies →62 of the 106 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
McMaster University · Sites in Canada
Ages 18–60
M.D. Anderson Cancer Center · Sites in United States
Ages 18–39
Eli Lilly and Company · Sites in United States, Belgium, Israel and 7 more countries
Ages 6–11
Eli Lilly and Company · Sites in United States
Ages 18–70
Columbia University · Sites in United States
Ages 40+
By country, each count listing its studies:
Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 1,350 Obesity studies recruiting now, 382 (28%) set no upper age limit and 864 (64%) stop at 75 or younger; 168 take children under 18; 490 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tirzepatide is the treatment under test here. Read study by study →
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 25 · Phase 3 28 · Phase 4 30
First in 2019; this study’s year is marked. 38 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 68 across 9,040 interventional studies indexed under Obesity.
Median enrollment 69 across the 106 interventional studies. Of the 25 that completed or were terminated, 14 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 106 have an industry lead sponsor. The 10 most frequent:
University Medical Centre Ljubljana is the lead sponsor of 298 studies on the registry; 73 are open to participants now.
20 studies in Obesity by University Medical Centre Ljubljana: 5 open now, 5 under way, none of them phase 3. Of 15 finished, 1 (7%) have results posted.
Among the 20 studies in Obesity by University Medical Centre Ljubljana, this one is the 11th largest by planned enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2026, is one of 13 in phase 4, and was the 20th registered.
University Medical Centre Ljubljana’s Obesity studies by the year they started, since 2011.
35 of the studies testing tirzepatide in Obesity that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07481747Phase 3Hudson BiotechEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | 2027-02-14 |
| NCT07738276Phase 3Shahid Beheshti University of Medical SciencesEvaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity | 2027-06-11 |
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
Add all 35 to your calendar (.ics) → With an account.
Among the 106 studies testing tirzepatide in Obesity, from their registry updates:
Among University Medical Centre Ljubljana’s 20 in Obesity:
This tab as a report to print or save as PDF → With an account.
This study investigates the effects of a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, tirzepatide, on corneal nerve morphology and other ocular parameters in adults with obesity. Participants, adult patients with obesity, will receive either tirzepatide or placebo over 24 weeks. Researchers will assess ophthalmological clinical status, corneal nerve changes, ocular surface, intraocular pressure, anterior-segment biometry and optical coherent tomography, and exophthalmometry. Orbital MRI will be performed in a subgroup of participants receiving tirzepatide. Optical coherence tomography and Optical coherence tomography angiography will be preformed to asses the posterior segment. The goal of this study is to investigate the effects of tirzepatide on corneal nerve morphology and functional consequences, as well as anterior segment parameters, during tirzepatide-induced weight loss, addressing an important gap in understanding the impact of incretin-based therapies on corneal nerves and anatomy of anterior eye segment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with obesity randomized to receive tirzepatide during the 24-week placebo-controlled study period. Ophthalmological assessments will be performed at baseline and Week 24 to evaluate treatment-related changes in ocular parameters.
Drug: Tirzepatide
Participants with obesity randomized to receive placebo during the initial 24-week study period. Ophthalmological assessments will be performed at baseline and Week 24 using the same protocol as in the tirzepatide group. Following the placebo-controlled period, participants will be offered tirzepatide treatment according to the study protocol.
Drug: Placebo
Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, will be administered by subcutaneous injection once weekly. Treatment will begin at 2.5 mg weekly, with dose escalation in 2.5 mg increments every 4 weeks, according to tolerability, up to a maximum dose of 15 mg weekly.
Matching placebo (saline solution) will be administered by subcutaneous injection once weekly using injection pens identical in appearance to those containing tirzepatide. The administration schedule and injection procedures will mirror those of the active treatment to maintain blinding.
Change in Corneal Nerve Fibre
Assessed by in vivo corneal confocal microscopy (Hedelberg Retina Tomograph -HRT3 Rostock Cornea Module, Heidelberg Engineering, Heidelberg Germany) and quantified with CCMetrics and SuperCCM softwares.
Time frame: Baseline to Week 24
Corneal sensitivity
Change in corneal sensitivity assessed using a semiquantitative cotton-wisp test. The corneal reflex will be evaluated by gently touching the corneal surface with a fine cotton fibre and classified into three categories: normal, diminished, or absent.
Time frame: Baseline to Week 24
Best-Corrected Visual Acuity Assessment
Best-corrected visual acuity (BCVA) will be assessed using Snellen charts. Objective refraction will be measured using an autorefractometer, while subjective refraction will be performed using a phoropter or trial frames and lenses.
Time frame: Baseline to Week 24
Intraocular pressure
Time frame: Baseline to Week 24
Anterior segment parameters
Assessed by Anterior segment optical coherent tomography Anterion (Heidelberg Engineering, Heidelberg Germany)
Time frame: Baseline to Week 24
Ocular surface
Change in tear break-up time
Time frame: Baseline to Week 24
Exophthalmometry
Change in Hertel measurement
Time frame: Baseline to Week 24
Orbital fat volume
Change in MRI-derived orbital fat volume in participants from subgroup receiving Tirzepatide
Time frame: Baseline to Week 24
OCT and OCTA of the retina
Posterior segment parameters will be assessed using optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) with the DRI OCT Triton system (Topcon, Inc., Tokyo, Japan).
Time frame: Baseline to Week 24
Change in Body Mass and composition
Measured primarily as changes in body weight, waist circumference and body composition measured by dual-energy X-ray absorptiometry (DXA).
Time frame: Baseline to Week 24
Plan to share: Yes — De-identified individual participant data (IPD) to be shared will include demographic data, anthropometric measurements, body composition assessments (body weight, waist circumference, and DXA-derived parameters), and ophthalmological assessment data, including corneal nerve fibre parameters obtained by in vivo corneal confocal microscopy, corneal sensitivity, best-corrected visual acuity, intraocular pressure, anterior segment OCT parameters, tear break-up time, Hertel exophthalmometry measurements, and posterior segment OCT and OCTA parameters. MRI-derived orbital fat volume measurements will be included for participants in the MRI subgroup. All shared data will be fully de-identified, and no directly identifiable personal information will be included.
Start is estimated for Dec 2026; primary completion for Nov 2027, 11 months later.
Of 190 non-industry phase 4 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 11 months is below that.
Counting every sponsor, half of 210 studies reached it within 31 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide
University Medical Centre Ljubljana →